Clinical significance of insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small cell lung cancer.
- Author:
Xiao-hong NING
1
;
Yu-zhou WANG
;
Chun-mei BAI
;
Ji LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; metabolism; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; drug therapy; metabolism; Male; Middle Aged; Receptor, IGF Type 1; metabolism; Retrospective Studies; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2010;32(4):366-370
- CountryChina
- Language:Chinese
-
Abstract:
UNLABELLEDOBJECTIVE; To explore the influence of the expression of insulin-like growth factor-1 receptor(IGF-1R)in end-stage non-small cell lung cancer.
METHODThe expression of IGF-1R was detected in 39 paraffin-embedded chemotherapy-naive non-small cell lung cancer tumor samples with immunohistochemical method,and the relationship between the outcomes of platinum-based chemotherapy and IGF-1R expression was analyzed.
RESULTSIGF-1R expression was detected in 21 cases (53.8%). The IGF-1R expression status shown no correlation with tumor pathological status,tumor differentiation status,history of smoking,as well as smoking index. Better outcomes of platinum-based chemotherapy were observed in patients with negative IGF-1R expression.
CONCLUSIONIGF-1R expression may be used to predict the effectiveness of the first-line platinum-based chemotherapy for end-stage non-small cell lung cancer.
